Mesothelioma.com Resources for Patients and their Families

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Brief Summary

Background:

- Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.

- Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.

- The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis.

- Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease.

Objectives:

-To allow sample acquisition for use in the study of mesothelioma.

Eligibility:

- All patients age greater than or equal to 2 years with malignant mesothelioma

- Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18

Design:

- Up to 1000 subjects will be enrolled.

- Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma.

- Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking.

- Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.

Tracking Information
First Received DateSeptember 21, 2013
Last Changed DateMarch 2, 2017
Start DateSeptember 5, 2013
Anticipated Primary Completion DateJuly 25, 2033
Primary Outcome Measures

Allow sample acquisition for use in the study of mesothelioma [Time Frame: Ongoing]

Descriptive Information
PhaseN/A
Study TypeObservational
Condition
  • Mesothelioma
Detailed Description

Background:

- Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.

- Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.

- The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis.

- Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease.

- In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.

- Mesothelin expression level has been correlated with improved overall survival in thymic cancer and with reduced overall survival in patients with lung cancer.

Objective:

-To allow sample acquisition for use in the study of mesothelioma and other mesothelin expressing cancers.

Eligibility:

- All patients age greater than or equal to 2 years with malignant mesothelioma

- All patients age greater than or equal to 2 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers

- Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18

Design:

- Up to 1000 subjects will be enrolled.

- Patients will be followed to determine the course of disease and to record any treatment received for the eligible mesothelin expressing cancer.

- Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking.

- Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.

Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment1000
GenderAll
Ages2 Years - 100 Years
Accepts Healthy VolunteersNo
Contact Lisa A Bengtson, R.N.
Email: bengtsonla@mail.nih.gov
Phone: (240) 760-6206
Eligibility Criteria

- INCLUSION CRITERIA:

- All patients greater than or equal to 2 years of age with malignant mesothelioma.

- All patients greater than or equal to18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers.

- Confirmed pathological diagnosis is required

- Ability and willingness of subject to provide informed consent to participation.

EXCLUSION CRITERIA:

- Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.

- Pregnant or breast feeding women will be eligible for this protocol, but will not undergo tumor biopsy.

- Active concomitant medical or psychological illnesses that may increase the risk to the subject or in adult patients, inability to obtain informed consent, at the discretion of the principal investigator.

Administrative Information
NCTIDNCT01950572
Responsible Party,
SponsorNational Cancer Institute (NCI)
Verification DateJanuary 11, 2017
Mesothelioma Doctors by State
  • Trust Funds Set Aside
  • VA Benefits Available
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

National Poison Prevention Week: Household Toxins to Avoid

National Poison Prevention Week: The Dangers of Asbestos

Joe Biden Gives a Cancer Moonshot Update at SXSW Conference

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: